Abstract
Mycobacteria are intrinsically resistant to most antimicrobials, which is generally attributed to the impermeability of their cell wall that considerably limits drug uptake. Moreover, like in other pathogenic bacteria, active efflux systems have been widely characterized from diverse mycobacterial species in laboratory conditions, showing that they can promote resistance by extruding noxious compounds prior to their reaching their intended targets. Therefore, the intracellular concentration of a given compound is determined by the balance between permeability, influx, and efflux.
Given the urgent need to discover and develop novel antimycobacterial compounds in order to design effective therapeutic strategies, the contributions to drug resistance made by the controlled permeability of the cell wall and the increased activity of efflux pumps must be determined. In this chapter, we will describe a method that allows (1) the measuring of permeability and the quantification of general efflux activity of mycobacteria, by the study of the transport (influx and efflux) of fluorescent compounds, such as ethidium bromide; and (2) the screening of compounds in search of agents that increase the permeability of the cell wall and efflux inhibitors that could restore the effectiveness of antimicrobials that are subject to efflux.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Du D, Wang-Kan X, Neuberger A et al (2018) Multidrug efflux pumps: structure, function and regulation. Nat Rev Microbiol 16:523–539
Pasipanodya JG, Gumbo T (2011) A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol 11:457–463
Piddock LJV (2019) The 2019 Garrod lecture: MDR efflux in gram-negative bacteria-how understanding resistance led to a new tool for drug discovery. J Antimicrob Chemother 74:3128–3134
De Rossi E, Aínsa JA, Riccardi G (2006) Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 30:36–52
Rodrigues L, Parish T, Balganesh M et al (2017) Antituberculosis drugs: reducing efflux=increasing activity. Drug Discov Today 22:592–599
Adams KN, Takaki K, Connolly LE et al (2011) Drug tolerance in replicating myco- bacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39–53
Ramón-García S, Mick V, Dainese E et al (2012) Functional and genetic characterization of the tap efflux pump in Mycobacterium bovis BCG. Antimicrob Agents Chemother 56:2074–2083
Ramón-García S, Martín C, Thompson CJ et al (2009) Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother 53:3675–3682
Lee RE, Hurdle JG, Liu J et al (2014) Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat Med 20:152–158
Balganesh M, Dinesh N, Sharma S et al (2012) Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob Agents Chemother 56:2643–2651
Balganesh M, Kuruppath S, Marcel N et al (2010) Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery. Antimicrob Agents Chemother 54:5167–5172
Viveiros M, Martins M, Rodrigues L et al (2012) Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev Anti-Infect Ther 10:983–998
Pule CM, Sampson SL, Warren RM et al (2016) Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother 71:17–26
Greulich KO (2004) Single molecule techniques for biomedicine and pharmacology. Curr Pharm Biotechnol 5:243–259
Jernaes MW, Steen HB (1994) Staining of Escherichia coli for flow cytometry: influx and efflux of ethidium bromide. Cytometry 17:302–309
Lomovskaya O, Bostian KA (2006) Practical applications and feasibility of efflux pump inhibitors in the clinic – a vision for applied use. Biochem Pharmacol 71:910–918
Blair JM, Piddock LJ (2016) How to measure export via bacterial multidrug resistance efflux pumps. mBio 7(4):e00840–16
Viveiros M, Martins A, Paixão L et al (2008) Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. Int J Antimicrob Agents 31:458–462
Ramón-García S, Martín C, Aínsa JA et al (2006) Characterization of tetracycline resistance mediated by the efflux pump tap from Mycobacterium fortuitum. J Antimicrob Chemother 57:252–259
Viveiros M, Martins M, Couto I et al (2008) New methods for the identification of efflux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps. Curr Drug Targets 9:760–778
Paixão L, Rodrigues L, Couto I et al (2009) Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. J Biol Eng 3:18
Rodrigues L, Ramos J, Couto I et al (2011) Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance. BMC Microbiol 11:35
Rodrigues L, Villellas C, Bailo R et al (2013) Role of the Mmr efflux pump in drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 57:751–757
Machado D, Coelho TS, Perdigão J et al (2017) Interplay between mutations and efflux in drug resistant clinical isolates of Mycobacterium tuberculosis. Front Microbiol 8:711
Rodrigues L, Machado D, Couto I et al (2012) Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol 12:695–700
Ballister ER, Samanovic MI, Darwin KH (2019) Mycobacterium tuberculosis Rv2700 contributes to cell envelope integrity and virulence. J Bacteriol 201:e00228–e00219
Xu W, DeJesus MA, Rücker N et al (2017) Chemical genetic interaction profiling reveals determinants of intrinsic antibiotic resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 61:e01334–e01317
Williams EA, Mba Medie F, Bosserman RE et al (2017) A nonsense mutation in Mycobacterium marinum that is suppressible by a novel mechanism. Infect Immun 85:e00653–e00616
Aguilar-Pérez C, Gracia B, Rodrigues L et al (2018) Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis. Antimicrob Agents Chemother 62:e00359–e00318
Mori G, Orena BS, Franch C et al (2018) The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. Tuberculosis (Edinb) 112:98–109
Bonnett SA, Ollinger J, Chandrasekera S et al (2016) A target-based whole cell screen approach to identify potential inhibitors of Mycobacterium tuberculosis signal peptidase. ACS Infect Dis 2:893–902
Nakamura de Vasconcelos SS, Caleffi-Ferracioli KR, Hegeto LA et al (2018) Carvacrol activity & morphological changes in Mycobacterium tuberculosis. Future Microbiol 13:877–888
Machado D, Pires D, Perdigão J et al (2016) Ion channel blockers as antimicrobial agents, efflux inhibitors, and enhancers of macrophage killing activity against drug resistant Mycobacterium tuberculosis. PLoS One 11:e0149326
Palomino JC, Martin A, Camacho M et al (2002) Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46:2720–2722
Costa SS, Lopes E, Azzali E et al (2016) An experimental model for the rapid screening of compounds with potential use against mycobacteria. Assay Drug Dev Technol 14:524–534
Peñuelas-Urquides K, Villarreal-Treviño L, Silva-Ramírez B et al (2013) Measuring of Mycobacterium tuberculosis growth. A correlation of the optical measurements with colony forming units. Braz J Microbiol 44:287–289
Rakhmawatie MD, Wibawa T, Lisdiyanti P et al (2019) Evaluation of crystal violet decolorization assay and resazurin microplate assay for antimycobacterial screening. Heliyon 5:e02263
Franzblau SG, DeGroote MA, Cho SH et al (2012) Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) 92:453–488
Acknowledgments
L. Rodrigues was supported by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 795924.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Rodrigues, L., Aínsa, J.A., Viveiros, M. (2021). Measuring Efflux and Permeability in Mycobacteria. In: Parish, T., Kumar, A. (eds) Mycobacteria Protocols. Methods in Molecular Biology, vol 2314. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1460-0_9
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1460-0_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1459-4
Online ISBN: 978-1-0716-1460-0
eBook Packages: Springer Protocols